Skip to main content

Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.

Publication ,  Journal Article
Hong, S; Funchain, P; Haddad, A; Crowe, J; Dalpiaz, N; Abraham, J
Published in: J Oncol Pract
March 2016

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Oncol Pract

DOI

EISSN

1935-469X

Publication Date

March 2016

Volume

12

Issue

3

Start / End Page

270 / 272

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Treatment Outcome
  • Piperazines
  • Phthalazines
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Germ-Line Mutation
  • Female
  • Carboplatin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hong, S., Funchain, P., Haddad, A., Crowe, J., Dalpiaz, N., & Abraham, J. (2016). Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. J Oncol Pract, 12(3), 270–272. https://doi.org/10.1200/JOP.2016.010710
Hong, Sanghee, Pauline Funchain, Abdo Haddad, Joseph Crowe, Nancy Dalpiaz, and Jame Abraham. “Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.J Oncol Pract 12, no. 3 (March 2016): 270–72. https://doi.org/10.1200/JOP.2016.010710.
Hong, Sanghee, et al. “Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.J Oncol Pract, vol. 12, no. 3, Mar. 2016, pp. 270–72. Pubmed, doi:10.1200/JOP.2016.010710.

Published In

J Oncol Pract

DOI

EISSN

1935-469X

Publication Date

March 2016

Volume

12

Issue

3

Start / End Page

270 / 272

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Treatment Outcome
  • Piperazines
  • Phthalazines
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Germ-Line Mutation
  • Female
  • Carboplatin